Coherus Oncology (CHRS) Non-Current Deferred Tax Liability (2023 - 2026)

Coherus Oncology has disclosed Non-Current Deferred Tax Liability across 4 years of filings, most recently posting $1.1 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $1.1 million, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (changed 0.0% YoY), and the FY2025 annual result was $1.1 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability came in at $1.1 million for Q1 2026 at Coherus Oncology, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.1 million in Q3 2023 to a low of $1.1 million in Q3 2023.
• The 4-year median for Non-Current Deferred Tax Liability is $1.1 million (2023), against an average of $1.1 million.
• Peak annual rise in Non-Current Deferred Tax Liability reached 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
• Coherus Oncology's Non-Current Deferred Tax Liability stood at $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then changed by 0.0% to $1.1 million in 2025, then changed by 0.0% to $1.1 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.